Real-world Experience of Rituximab in Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is a relapsing–remitting disease often requiring more than one line of therapy. Rituximab is a recommended second-line therapy, but the real-world data on its efficacy and safety from resource constraint settings is limited. We aimed to analyze the safety and efficacy o...

詳細記述

保存先:
書誌詳細
出版年:Indian J Hematol Blood Transfus
主要な著者: Mishra, Kundan, Kumar, Suman, Jandial, Aditya, Sahu, Kamal Kant, Sandal, Rajeev, Ahuja, Ankur, Khera, Sanjeev, Uday, Yanamandra, Kumar, Rajiv, Kapoor, Rajan, Verma, Tarun, Sharma, Sanjeevan, Singh, Jasjit, Das, Satyaranjan, Chatterjee, Tathagat, Sharma, Ajay, Nair, Velu
フォーマット: Artigo
言語:Inglês
出版事項: Springer India 2021
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8239077/
https://ncbi.nlm.nih.gov/pubmed/34267459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12288-020-01351-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料